Leerink Assumes Kura Oncology (KURA) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts KURA Hot Sheet
Price: $8.13 -17.71%
Rating Summary:
18 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
18 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Leerink analyst Asthika Goonewardene assumes coverage on Kura Oncology (NASDAQ: KURA) with a Outperform rating and a price target of $21.00.
For an analyst ratings summary and ratings history on Kura Oncology click here. For more ratings news on Kura Oncology click here.
Shares of Kura Oncology closed at $10.68 yesterday.
You May Also Be Interested In
- H.C. Wainwright Assumes MiNK Therapeutics (INKT) at Buy
- Guggenheim Starts Lockheed Martin (LMT) at Buy
- Bernstein SocGen Group Starts Pfizer Ltd (PFIZ:IN) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
